Recent 8-K filings for INM
Highest-materiality recent filing
InMed to merge with Mentari; pre-Merger InMed holders to own ~1.51% of combined company
- Merger: InMed shareholders to own ~1.51% of combined entity; Mentari stockholders ~98.49%.
- Concurrent $290M private placement led by Fairmount; funds operations through 2028.
-
InMed to merge with Mentari; pre-Merger InMed holders to own ~1.51% of combined company
Merger: InMed shareholders to own ~1.51% of combined entity; Mentari stockholders ~98.49%.
-
InMed amends Armistice option exercise price from $16.60 to $0.80 per share
Up to 278,761 common shares subject to options; exercise price reduced to $0.80 from $16.60.
-
InMed Q3 net loss $3.0M; INM-901 Alzheimer's data positive, BayMedica exit
Net loss from continuing ops $2.8M (Q3 FY2026) vs $2.1M prior year; total net loss $3.0M.
-
InMed reduces exercise price of Sabby and Wainwright preferred investment options to $0.80
Sabby options now exercisable at $0.80 (was $2.436) for up to 2,151,478 shares.
-
InMed receives Nasdaq notice of bid price deficiency; 180 days to cure
Received Nasdaq notice on March 27, 2026; closing bid price below $1.00 for 30 consecutive days (Feb 11–Mar 26).
-
InMed reports positive INM-901 data in human brain organoid neuroinflammation models
INM-901 reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease.
-
InMed to wind down BayMedica commercial ops; focus shifts to Alzheimer's, AMD pipeline
Board ratified wind-down of BayMedica commercial operations due to H.R. 5371 uncertainty; completion expected by June 30, 2026.
-
Net loss of $2.03M for Q2 FY2026 (EPS -$0.51) vs net loss $2.58M in prior year; gross profit fell to $184K from $461K.
-
H.R. 5371, signed into law, will prohibit BayMedica's commercial inventory of rare, non-intoxicating cannabinoids as of Nov 12, 2026, in its current form.
-
InMed announces positive PK data for Alzheimer's candidate INM-901 in large animal model
Oral formulation of INM-901 showed robust bioavailability over 7-day dosing in large animals.
-
InMed reports FY2025 net loss of $8.2M; BayMedica revenue up 8% to $4.9M
Net loss $8.2M vs $7.7M prior year; diluted EPS ($8.36) vs ($20.14) on higher share count.
-
InMed to present INM-901 preclinical data at AAIC 2025; long-term study shows multi-modal activity
Preclinical data from INM-901 program presented at Alzheimer's Association International Conference (AAIC) 2025 in Toronto.
-
InMed Pharma raises $5M in private placement of pre-funded warrants and options
Gross proceeds ~$5M from 1,952,363 pre-funded warrants ($0.0001 exercise) and 1,952,363 preferred investment options at $2.436/share.
-
InMed's INM-901 reduces neuroinflammation markers in Alzheimer's ex vivo study
INM-901 statistically significantly reduced pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro in LPS-induced ex vivo model.
-
InMed special meeting lacks quorum for share issuance vote; appoints new auditor CBIZ
Special meeting on June 13, 2025 lacked quorum; ~60% of voted shares favored share issuance proposal but no vote held. Board evaluating next steps.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.60 · Most common event other_material